MedTrace Logo

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

NCT05782270 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2025-11-18

No results posted yet for this study

Summary

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.

Conditions

  • Anticoagulation
  • Coronary Endarterectomy

Interventions

DRUG

DAPT

Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)

OTHER

CE+CABG

Coronary endarterectomy combined with coronary artery bypass grafting

DRUG

Warfarin

dual antiplatelet therapy combined with warfarin

Sponsors & Collaborators

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-11
Primary Completion
2025-09-25
Completion
2026-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05782270 on ClinicalTrials.gov